Compare Stocks: EGRX, DWTX, CRVO, and SCYX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVO CervoMed	$3.22 -1.8%	$2.72	$2.13 ▼ $10.00	$49.59M	-0.75	237,545 shs	231,609 shs
DWTX Dogwood Therapeutics	$1.40 -0.7%	$1.91	$1.28 ▼ $7.04	$47.93M	1.92	68,325 shs	66,325 shs
EGRX Eagle Pharmaceuticals	$0.97	$0.75	$0.00 ▼ $3.00	$23.38M	0.83	7,753 shs	N/A
SCYX SCYNEXIS	$4.08 -3.3%	$4.95	$3.53 ▼ $9.12	$41.99M	1.06	552,621 shs	119,547 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVO CervoMed	-1.83%	+6.62%	+28.29%	-9.80%	-63.82%
DWTX Dogwood Therapeutics	-0.71%	-4.11%	-27.84%	-1.41%	-78.06%
EGRX Eagle Pharmaceuticals	0.00%	0.00%	+29.33%	+44.78%	-67.67%
SCYX SCYNEXIS	-3.32%	-20.31%	-16.90%	-6.85%	-34.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVO CervoMed	$3.22 -1.8%	$2.72	$2.13 ▼ $10.00	$49.59M	-0.75	237,545 shs	231,609 shs
DWTX Dogwood Therapeutics	$1.40 -0.7%	$1.91	$1.28 ▼ $7.04	$47.93M	1.92	68,325 shs	66,325 shs
EGRX Eagle Pharmaceuticals	$0.97	$0.75	$0.00 ▼ $3.00	$23.38M	0.83	7,753 shs	N/A
SCYX SCYNEXIS	$4.08 -3.3%	$4.95	$3.53 ▼ $9.12	$41.99M	1.06	552,621 shs	119,547 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVO CervoMed	-1.83%	+6.62%	+28.29%	-9.80%	-63.82%
DWTX Dogwood Therapeutics	-0.71%	-4.11%	-27.84%	-1.41%	-78.06%
EGRX Eagle Pharmaceuticals	0.00%	0.00%	+29.33%	+44.78%	-67.67%
SCYX SCYNEXIS	-3.32%	-20.31%	-16.90%	-6.85%	-34.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVO CervoMed	2.71	Moderate Buy	$21.00	552.17% Upside
DWTX Dogwood Therapeutics	2.00	Hold	$12.00	757.14% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
SCYX SCYNEXIS	2.33	Hold	$33.00	708.82% Upside

Current Analyst Ratings Breakdown

Latest EGRX, DWTX, CRVO, and SCYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	DWTX Dogwood Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	CRVO CervoMed	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/13/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	SCYX SCYNEXIS	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$24.00 ➝ $33.00
8/12/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	SCYX SCYNEXIS	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	DWTX Dogwood Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVO CervoMed	$4.01M	12.14	N/A	N/A	$1.97 per share	1.63
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
EGRX Eagle Pharmaceuticals	$257.55M	0.05	$2.43 per share	0.40	N/A	∞
SCYX SCYNEXIS	$20.60M	1.97	N/A	N/A	$9.07 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVO CervoMed	-$26.97M	-$3.22	N/A	N/A	N/A	N/A	-156.02%	-128.34%	11/12/2026 (Estimated)
DWTX Dogwood Therapeutics	-$34.26M	-$8.95	N/A	N/A	N/A	N/A	-75.55%	-40.28%	11/5/2026 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	$1.18	0.82	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
SCYX SCYNEXIS	-$8.61M	-$2.09	N/A	N/A	N/A	N/A	-44.15%	-32.61%	11/4/2026 (Estimated)

Latest EGRX, DWTX, CRVO, and SCYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	DWTX Dogwood Therapeutics	-$0.15	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	SCYX SCYNEXIS	-$0.72	N/A	N/A	N/A	$0.13 million	N/A
8/13/2026	Q2 2026	DWTX Dogwood Therapeutics	-$0.14	-$0.34	-$0.20	-$0.34	N/A	N/A
8/10/2026	Q2 2026	SCYX SCYNEXIS	-$0.5067	$0.63	+$1.1367	$0.63	$0.08 million	$0.24 million
8/7/2026	Q2 2026	CRVO CervoMed	-$0.8640	-$0.64	+$0.2240	-$0.64	$0.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVO CervoMed	N/A	8.57	8.57
DWTX Dogwood Therapeutics	N/A	3.89	3.89
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	9.65	9.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVO CervoMed	25.15%
DWTX Dogwood Therapeutics	9.05%
EGRX Eagle Pharmaceuticals	85.36%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
CRVO CervoMed	35.80%
DWTX Dogwood Therapeutics	0.30%
EGRX Eagle Pharmaceuticals	28.90%
SCYX SCYNEXIS	4.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVO CervoMed	15	15.12 million	9.71 million	Not Optionable
DWTX Dogwood Therapeutics	8	33.99 million	33.89 million	N/A
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
SCYX SCYNEXIS	29	9.95 million	9.54 million	Optionable

EGRX, DWTX, CRVO, and SCYX Headlines

Recent News About These Companies

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease

October 7 at 6:45 PM | marketscreener.comM

SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?

October 7 at 4:00 AM | defenseworld.netD

SCYNEXIS (NASDAQ:SCYX) Shares Cross Above Fifty Day Moving Average - What's Next?

October 7 at 3:01 AM | americanbankingnews.com

SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

October 7 at 2:59 AM | marketbeat.com

SCYNEXIS Reports Favorable Phase 1 Results For ADPKD Drug

October 6, 2026 | rttnews.com

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease ...

October 6, 2026 | markets.businessinsider.com

SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026

October 6, 2026 | quiverquant.comQ

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

October 6, 2026 | globenewswire.com

Contrasting Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)

October 2, 2026 | americanbankingnews.com

SCYNEXIS Secures BARDA Funding for Antifungal Pipeline

September 30, 2026 | theglobeandmail.com

SCYNEXIS Secures BARDA Funding for Antifungal Pipeline

September 30, 2026 | theglobeandmail.com

SCYNEXIS, Inc. (NASDAQ: SCYX) Wins $18.5 Million for Antifungal

September 30, 2026 | americanbankingnews.com

Scynexis stock surges on $214M BARDA contract for SCY-247

September 28, 2026 | finance.yahoo.com

Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract

September 28, 2026 | finance.yahoo.com

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

September 28, 2026 | globenewswire.com

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

September 22, 2026 | markets.businessinsider.com

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.

September 22, 2026 | globenewswire.com

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

September 15, 2026 | globenewswire.com

SCYNEXIS Names Sanjay Subramanian as CFO

September 10, 2026 | finance.yahoo.com

Scynexis Names Sanjay Subramanian CFO

September 10, 2026 | rttnews.com

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

September 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, DWTX, CRVO, and SCYX Company Descriptions

CervoMed NASDAQ:CRVO

$3.22 -0.06 (-1.83%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.25 +0.03 (+1.02%)

As of 10/9/2026 07:55 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Dogwood Therapeutics NASDAQ:DWTX

$1.40 -0.01 (-0.71%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.45 +0.05 (+3.50%)

As of 10/9/2026 07:55 PM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Eagle Pharmaceuticals NASDAQ:EGRX

$0.97 0.00 (0.00%)

As of 10/8/2026

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

SCYNEXIS NASDAQ:SCYX

$4.08 -0.14 (-3.32%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.08 +0.00 (+0.12%)

As of 10/9/2026 07:38 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, DWTX, CRVO, and SCYX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, DWTX, CRVO, and SCYX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, DWTX, CRVO, and SCYX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, DWTX, CRVO, and SCYX Company Descriptions

CervoMed NASDAQ:CRVO

Dogwood Therapeutics NASDAQ:DWTX

Eagle Pharmaceuticals NASDAQ:EGRX

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, DWTX, CRVO, and SCYX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, DWTX, CRVO, and SCYX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, DWTX, CRVO, and SCYX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, DWTX, CRVO, and SCYX Company Descriptions

CervoMed NASDAQ:CRVO

Dogwood Therapeutics NASDAQ:DWTX

Eagle Pharmaceuticals NASDAQ:EGRX

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools